Results 241 to 250 of about 4,146,035 (404)

Mechanism of action of lncRNA-NEAT1 in immune diseases. [PDF]

Front Genet
Zhang RX, Zhang ZX, Zhao XY, Liu YH, Zhang XM, Han Q, Wang XY.   +6 more
europepmc   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Mechanism of Action of circRNA/miRNA Network in DLBCL. [PDF]

Noncoding RNA
Golovina E, Eaton C, Cox V, Andel J, Savvulidi Vargova K.   +4 more
europepmc   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Mechanism of action and therapeutic value of anoctamin-1 in gastrointestinal cancers. [PDF]

Front Immunol
Zhang X, Lin J, Xu H, Zhou Y, Mu Z, Shi R, Lv Y.   +6 more
europepmc   +1 more source

Mechanism of action of pullulanase

FEBS Letters, 1969
G.S. Drummond, Han Tai, William J. Whelan, Eric E. Smith   +3 more
openaire   +3 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action. [PDF]

ACS Omega
Riaz A, Khan MFA, Jalil A, Rehman AU, Ahmed N, Mubarak Z, Parhizkar M, Muqaddas H.   +7 more
europepmc   +1 more source

Further Studies on the Mechanism of Action of Carbamyl Phosphate Synthetase

, 1959
Robert L. Metzenberg, Margaret Marshall, P P Cohen, Wilmer G. Miller   +3 more
openalex   +1 more source

CYTOCHEMICAL MECHANISMS OF PENICILLIN ACTION VIII [PDF]

, 1949
Robertson Pratt, Jean Dufrénoy
openalex   +1 more source